摘要
目的进一步评价一类抗癌新药人参皂甙Rg3治疗肺癌的疗效。方法采用临床对照试验方法,观察化疗联合人参皂甙Rg3对30例中晚期肺癌的疗效及其毒副作用,对照组单纯化疗,试验组在化疗的同时加用20(R)-Rg3,疗程6-8周。结果化疗联合人参皂甙Rg3能显著提高化疗疗效,试验组有效率(PR+CR)为36.6%,对照组为16.7%(P<0.05);对不同组织学类型肺癌之间的疗效无显著性差异(P>0.05)。结论人参皂甙Rg3与化疗合用能显著提高肺癌患者的治疗效果。
Objective To make a further evaluation of curative effect of ginsenoside Rg3 on lung cancer. Methods Sixty patients with moderate ound advanced lung cancers were averagely divided into both the experimental and control groups. Thirty patients in the experimental group received 20(R) - ginsenoside Rg3 treatment and chemotherapy from 6 to 8 weeks.Thirty patients in the control group only received chemotherpy from 6 to 8 weeks. Results The clinical relief rate of patients in the experimental group was 36.6% , which was higher than that (16.7%) of the patients in the control group ( P < 0.05) . The insignificantly different effects on histologically different types of lung cancers were observed in the experimental group ( P > 0.05) .Conclusion Combined 20(R)-ginsenoside Rg3 with chemotherapy can improve clinical therapeutic effect on the lung cancer.
出处
《华南国防医学杂志》
CAS
2005年第1期4-6,共3页
Military Medical Journal of South China
